Secondary analysis of the phase II UTOLA trial: ESR1 mutations were found in 8 of 137 (6%) endocrine-naive advanced endometrial cancers, all low-grade endometrioid NSMP (22% of metastatic NSMP low-grade); survival after platinum did not differ significantly (P=0.114).
Secondary analysisn = 137
Blanc-Durand et al. ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial